© 1996 American Heart Association, Inc.
Articles |
Inhibition of Matrix Metalloproteinase Activity Inhibits Smooth Muscle Cell Migration but Not Neointimal Thickening After Arterial Injury
From the Department of Pathology, University of Washington, Seattle.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and Methods Results Discussion References |
|---|
Abstract Smooth muscle cell (SMC) migration and replication are important for neointimal formation after arterial injury. Migration of SMCs requires degradation of basement membrane and extracellular matrix surrounding the cell, and our previous work has shown a correlation between expression of two matrix-degrading metalloproteinases (MMPs), MMP-2 and MMP-9, and smooth muscle migration into the intima in the balloon catheter–injured rat carotid artery. In the present study, an MMP inhibitor, GM 6001, was administered to rats for various times after balloon injury of the carotid artery. Inhibition of MMP activity resulted in a 97% decrease in the number of SMCs that migrated into the intima by 4 days after injury, and lesion growth was retarded by continuous treatment with GM 6001 for up to 10 days after injury. At 10 days, intimal area in GM 6001–treated rats was 0.035±0.008 mm2 compared with 0.095±0.01 mm2 in the control group. Neither intimal nor medial SMC replication rates were decreased by GM 6001 treatment, supporting our hypothesis that the decrease in lesion size was due to inhibition of MMP-mediated migration and not inhibition of replication. By 14 days after injury, however, intimal area and SMC number were the same in control and inhibitor-treated rats. An increased rate of SMC replication in the GM 6001 rats (replication rates at 10 days were 56.7±10.0% in the GM 6001 group and 16.97±1.73% in the control group) contributed to "catch-up" growth of the neointima. Thus, it appears that inhibiting SMC migration with MMP inhibitors is not sufficient to inhibit lesion growth, and lesion size eventually catches up to control via increased SMC replication.
Key Words: matrix metalloproteinases • artery • rat • injury • neointima
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and Methods Results Discussion References |
|---|
The intima of a normal rat carotid artery does not contain SMCs, but within days after balloon catheter injury a neointima develops, consisting predominantly of SMCs that have migrated across the internal elastic lamina from the media and then replicated.1 SMC migration is therefore a key step in the development of intimal lesions. The process of migration presumably requires degradation of basement membrane and extracellular matrix surrounding the cell, and there is increasing evidence that SMCs produce extracellular matrix–degrading proteinases after arterial injury. These cells express mRNA for urokinase and tissue-type plasminogen activators after balloon catheter injury,2 3 4 5 and tissue-type plasminogen activator activity is increased at 4 days after arterial injury, coincident with SMC migration to the intima. Further, the addition of tranexamic acid, a plasminogen activator inhibitor, inhibited SMC migration.3 Plasminogen activators catalyze the conversion of plasminogen to plasmin, which in turn can degrade several matrix molecules and can activate MMPs, a family of molecules involved in degradation and remodeling of connective tissues.6 Indeed, we have shown induction of an 88-kD gelatinolytic enzyme (MMP-9) and increased activity of a 62-kD gelatinase (MMP-2), coincident with SMC migration after balloon catheter injury of the rat carotid artery.7 After vascular injury, SMCs should be capable of digesting most if not all matrix components of the arterial wall, and we believe this proteolytic activity is necessary to permit their migration into the intima.
One question not yet answered is whether the MMPs play a role in the development of the intimal thickening of atherogenesis and restenosis after angioplasty. Some support for a role of MMPs in lesions has come from recent studies that have demonstrated MMP-1, -2, -3, and -9 by immunocytochemistry and by in situ hybridization in human atherosclerotic plaque specimens and in diffuse and thickened intimas.8 9 10 In the present study we administered an MMP inhibitor, GM 6001, to investigate the role of MMPs in intimal lesion development after balloon catheter injury of the rat carotid artery. Inhibition of MMP activity resulted in a nearly complete inhibition of SMC migration into the intima, and at early times after injury, a significant reduction in neointimal thickening was observed. This study suggested that MMPs are important mediators of tissue remodeling after arterial injury, permitting the migration of SMCs into the newly formed intima. The intimal lesion eventually increased to control levels because of increased SMC replication rate in the GM 6001–treated rats.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and Methods Results Discussion References |
|---|
Surgery
Male Sprague-Dawley rats (3 to 4 months old) from Bantin and Kingman Laboratories (Edmonds, Wash) were used in all experiments. Rats were anesthetized by intraperitoneal injection of xylazine (Anased; Lloyd Laboratories), 4.6 mg/kg body weight, and ketamine (Ketaset; Aveco Co Inc), 70 mg/kg body weight. A midline incision in the neck was made to expose the left external carotid artery. A 2F balloon catheter (Baxter Healthcare Co) was introduced through the left external carotid artery and passed into the common carotid artery. The balloon was distended with saline until a slight resistance was felt, then was rotated while pulling back through the common carotid to denude the vessel of endothelium. This procedure was repeated two more times; then the catheter was removed, the external carotid ligated, and the wound closed.
MMP Inhibitor
A peptide hydroxamic acid (GM 6001), supplied
by Glycomed Inc,
was used to inhibit MMP activity in injured rat carotid
arteries.11 The ability of this inhibitor to
effectively inhibit rat arterial MMPs was tested by
incubating a zymogram gel containing rat arterial extracts
with incubation buffer containing 0.5 mmol/L GM 6001. GM 6001
completely inhibited all gelatinolytic activity on
the zymogram (results not shown). Immediately before balloon catheter
injury, rats were injected IP with 100 mg/kg GM 6001 dissolved in 4%
CMC. Control rats were injected with 4% CMC vehicle. Plasma GM 6001
concentration was measured by high-performance liquid
chromatography in four rats at 5, 14, and 24 hours
after initial IP injection of GM 6001 and injury. The rats were
injected daily with either GM 6001 or CMC until they were killed at 2,
4, 7, 10, or 14 days after carotid artery injury. For all time points,
to label all cells entering S-phase during the last 24 hours before
sacrifice, three injections of BrdU (Boehringer Mannheim Corp)
were given subcutaneously (25 mg/kg body weight) at 17, 9, and 1
hour(s) before death. Rats were killed by IV injection of sodium
pentobarbitol (Anthony Products Co). Lactated Ringer's injection
USP (Baxter) was infused at a pressure of 120 mm Hg retrogradely via a
catheter placed in the abdominal aorta. The vessels were then perfusion
fixed with 0.1 mol/L phosphate-buffered 4%
paraformaldehyde at 110 mm Hg. Vessels were excised and
immersed in 4% paraformaldehyde for 1 hour, and then
transferred to Ringer's solution.
In the rats killed 4 days after balloon injury, a 1-cm length of vessel was excised from the middle of the fixed common carotid and used to determine SMC migration as previously described.7 Briefly, migration was measured by staining the intimal cell nuclei with an antibody against histone H1 (MAB 1276, Chemicon International Inc) and counting the number of cells in the intima at 4 days after injury. In rats killed at 2, 4, 7, 10, and 14 days after injury, 5-mm lengths of the carotid arteries were cut and embedded in paraffin, and histological cross sections were prepared. We measured medial (2- and 4-day injury) and intimal (7-, 10-, and 14-day injury) SMC replication rates by immunostaining for BrdU and determining the percentage of BrdU-labeled cells present, as previously described.12 Intimal lesion area was measured by photographing the vessel cross sections, scanning the photographs with a Hewlett Packard Scan Jet IIp scanner, and measuring intimal and medial areas by using public domain NIH IMAGE (written by Wayne Rasband at the US National Institutes of Health and available from the Internet by anonymous FTP from zippy.nimh.nih.gov or on floppy disk from NTIS, 5285 Port Royal Rd, Springfield, VA 22161, part number PB93-504868) version 1.55 software run on a Macintosh IIsi computer. Lumen area was determined by tracing around the inside edge of the vessel and quantitating the area inside the circle. Intimal area was measured as the area encompassed by the internal elastic lamina minus the lumen area.
GM 6001 Delay Experiments
In an attempt to define a critical
period for SMC migration from
the media to the intima, we altered the time of administration of the
MMP inhibitor. In one group (First 7D GM 6001), GM 6001 was
administered daily at a dose of 100 mg/kg per day for the first 7 days
after balloon catheter injury, then stopped before the rats were
finally killed at 14 days postinjury. In a second set of experiments
(Second 7D GM 6001), we balloon injured the carotid artery and delayed
GM 6001 administration for 7 days. GM 6001 was administered daily at a
dose of 100 mg/kg per day between 7 and 14 days postinjury, before the
rats were killed at 14 days. The controls for these two groups included
a group administered 4% CMC for the first 7 days after injury (First
7D Control) and a group in which 4% CMC was delayed until 7 to 14 days
after injury (Second 7D Control). BrdU was administered, and the rats
were killed and the carotids perfusion fixed as described above. We
measured intimal area on cross sections and determined intimal SMC
replication rates as described above.
Statistical Analysis
Differences in SMC migration at 4 days
and differences in medial
SMC replication rates between control and GM 6001–treated rats at 2
and 4 days after injury were analyzed by unpaired Student's
t test. Differences between control and GM 6001–treated
rats in carotid intimal area, intimal SMC replication rate, and the
total number of intimal cells at 7, 10, and 14 days after injury were
assessed by unpaired Student's t test. Differences in
carotid intimal area and SMC replication rate in the 14-day-delay
experiments were analyzed by ANOVA followed by Fisher's
protected least significant difference for pairwise comparisons.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and Methods Results Discussion References |
|---|
Previous studies have shown that MMP-2 and MMP-9 activities were increased coincident with SMC migration into the intima after balloon injury of the rat carotid.7 These data led us to hypothesize that the MMPs are functionally important in mediating this cell migration. In the present studies, an MMP inhibitor, GM 6001,11 almost completely inhibited the migration of SMCs to the intima after administration for 4 days after balloon catheter injury (Fig 1
). The number
of intimal SMCs was decreased from 99.7±30.8 cells/mm2 in
vehicle-infused control rats to 2.84±0.79 cells/mm2 in
GM 6001–treated rats (P=.007). No significant difference
in
medial SMC replication rate was observed between the control and GM
6001–treated groups at 2 or 4 days after injury (Fig 2).
|
|
Growth of the intimal lesion occurs through migration of SMCs from the
media, as well as intimal SMC replication and matrix synthesis. Since
migration of SMCs by necessity precedes intimal SMC replication, we
asked whether inhibition of SMC migration would retard the growth of
intimal lesions. Intimal thickening was greatly reduced after treatment
with GM 6001 at early times after injury (Fig 3). At 7
days intimal area in the GM 6001–treated rats was 0.023±0.004
mm2, significantly less than the intimal area in the
control rats, 0.046±0.009 mm2 (P=.0281). At
10
days after injury intimal area in the GM 6001 rats was still
significantly lower than in control rats (P=.005). By 14
days, however, intimal areas were not different in control and GM
6001–treated rats.
|
Although we know that GM 6001 inhibits early migration of SMCs from
media to intima, inhibition of lesion growth could also be affected by
a change in intimal SMC replication. To test whether GM 6001 had such
an effect, intimal SMC replication rates were measured at 7, 10, and 14
days after injury, and the results are shown in Fig 4.
At no time was SMC replication rate inhibited in the GM 6001–treated
groups. In fact, at 10 days after injury SMC replication rate was 3.3
times greater in the GM 6001 group than the control group
(P=.0045). By 14 days after injury, SMC replication rate in
the GM 6001–treated rats declined to values not significantly
different from the control rats. We were concerned that the high
replication rate in GM 6001–treated rats might result in increased
intimal SMC number; however, total intimal SMC number was not
significantly different in GM 6001–treated and control rats at 14 days
after injury (Fig 5).
|
|
Since inhibiting MMP activity blocked cell migration but did not decrease SMC replication, we used GM 6001 to try to define the critical period over which SMC migration occurred. GM 6001 was administered daily for the first 7 days after balloon catheter injury, then stopped, and the rats were finally killed at 14 days postinjury (First 7D GM 6001). In a second set of experiments, the carotid artery was injured, and GM 6001 was administered for 7 to 14 days postinjury (Second 7D GM 6001). The controls for these last two groups included a group administered 4% CMC for the first 7 days after injury (First 7D Control) and a group in which 4% CMC was delayed until 7 to 14 days after injury (Second 7D Control). No significant difference was noted between these two control groups for any parameter measured, so the values were combined to simplify representation in figures.
If GM 6001 treatment was administered for the first 7 days after injury
and the rats killed at day 14 (First 7D GM 6001), no significant
difference in lesion area compared with control rats was observed (Fig
6). Intimal lesion area was 0.180±0.031 mm2
in control rats and 0.195±0.018 mm2 in First 7D GM 6001
rats. When GM 6001 treatment was given for days 7 through 14 (Second 7D
GM 6001), the final lesion size at 14 days, 0.173±0.022
mm2, was not different from controls or the First 7D
GM 6001 rats. In all groups, intimal SMC replication rates at 14 days
declined to low levels and were not significantly different from
control rates: control, 8.10±1.96%; First 7D GM 6001,
10.42±1.47%;
and Second 7D GM 6001, 7.46±1.52% (Fig 7).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and Methods Results Discussion References |
|---|
Rats do not have SMCs normally resident in the arterial intima, yet the thickened intimal lesions that develop after injury consist predominantly of SMCs and matrix. Therefore, the migration of SMCs from media to intima is a necessary step for the development of lesions in rat arteries. In previous work, we have found that migration of SMCs in the injured carotid artery was stimulated by platelet-derived growth factor B, and involvement of the plasmin-plasminogen activator system was critical.3 In the present study we show that MMP activity also plays a critical role in lesion development but is not able to ultimately affect the size of these lesions.
Our aim in this study was to block the activity of those MMPs that we
believe are important in SMC migration. The metalloproteinase
inhibitor used, GM 6001, is not specific for individual
members of the MMP family, and the steady state plasma concentrations
achieved in the present experiments, 
50 nmol/L, were well in
excess of the Ki values for MMP-9 and MMP-2 (0.2 and 0.5
nmol/L, respectively; R.E. Galardy, unpublished data, 1995). This lack
of specificity of the inhibitor was not a major concern to
us, since we have found that expression of active MMP-9 is induced
after balloon catheter injury to rat arteries and also that there is
increased activation of constitutive MMP-2 coincident with SMC
migration into the intima.7 Further, we have found no
evidence of MMP-3 or MMP-1 synthesis by rat vascular smooth muscle in
vivo7 ; consequently, we believe that MMP-9 and MMP-2 are
the principle mediators of migration for arterial SMCs. Our
findings are supported by the work of Jenkins et al,13 who
observed a similar pattern of MMP-9 and MMP-2 expression after balloon
catheter injury of the rat carotid artery.
There is considerable evidence that MMPs mediate cell migration during tumor cell invasion and metastasis, blastocyst implantation, and placentation.14 15 16 17 Our hypothesis that MMPs are important in SMC proliferation and migration is supported by the recent observations of Southgate et al18 that SMCs migrating from rabbit aortic explants in vitro expressed both MMP-2 and MMP-9 and synthetic MMP inhibitors blocked both SMC proliferation and migration from the explants. Similarly, others have shown that invasion of SMCs through basement membranes in chemotaxis chamber assays was dependent on production of MMP-2 and could be inhibited by treatment with peptide MMP inhibitors.19 Taken together with our current results, these prior studies provide evidence for MMP mediation of SMC migration both in vivo and in vitro.
Our data showed that a significant inhibition of migration at day 4 and significant decreases in lesion size at 7 and 10 days after injury were obtained with the MMP inhibitor. Thus, MMP-mediated migration significantly contributes to lesion growth, at least for the first 10 days after injury. The continued presence of the inhibitor, however, did not ultimately reduce the intimal lesion size, since 14 days after injury the intima in the GM 6001–treated rats was equal to that of control rats. From our data it would appear that a prolonged peak of intimal SMC replication rate in GM 6001–treated rats was responsible for this "catch-up" in lesion size. We do not understand the factors mediating the prolonged increase in intimal SMC replication, although it is unlikely that the MMP inhibitor is directly involved, since administration of the drug made no difference to the replication rates of medial cells 2 and 4 days after injury or to intimal cells 7 and 14 days after injury. One possibility is that since matrix degradation is inhibited by GM 6001, there is a change in the cell–extracellular matrix interactions. In vitro, cell attachment to extracellular matrix components is a prerequisite for proliferation in response to growth stimuli and also prevents apoptosis.20 21 In our study, blocking MMP activity may have prevented cells from detaching themselves from the matrix, rendering them susceptible to continued growth stimulation, and hence an enhanced replication was observed. Other possibilities are that changes in extracellular matrix composition directly influenced cell replication or altered the balance of active growth factors sequestered in the matrix. Additional growth regulatory mechanisms must have been present, because SMC replication rate did ultimately decrease by 14 days despite continued inhibition of MMP activity.
It is difficult to measure SMC migration in vivo, since both cell
migration and replication contribute to growth of the
intima.22 Our data showed that GM 6001 acted as a specific
inhibitor of migration at 4 days after injury, and this
finding led us to attempt to determine the duration of migration in the
injured rat carotid artery. Delaying GM 6001 treatment for the first
week after injury and then giving the drug between 7 and 14 days had no
effect on lesion size measured at 14 days. This result implies that
migration of SMCs into the intima did not contribute significantly to
lesion growth during the second week after injury. Somewhat puzzling
are the data on GM 6001 administration for the first 7 days after
injury and then withdrawal for the next 7 days. We have shown that
after 7 days a smaller lesion would be expected (Fig 3
), and
yet when
these lesions were examined at 14 days, no significant difference was
observed. This result might imply that SMC migration still occurs
during this time, but as pointed out above, the SMC replication of
these treated intimas is increased within this time frame; thus, it is
not possible to draw any firm conclusions as to whether migration
occurs at this time. Considering the data from the 7-day continuous
administration and the delay experiments together, we suggest that SMC
migration occurs within the first 7 days in the injured artery, since
blocking migration over this time led to a significant decrease in
lesion size. However, any migration occurring between day 7 and day 14
is relatively insignificant compared with intimal cell replication, and
so inhibition of cell migration for the second week after injury has no
effect on overall lesion size.
Finally, these data show that any early change in the growth of arterial lesions can be compensated for by intimal cell replication. Over the past 10 years we have characterized lesion growth in the rat carotid artery injury model and divided the response to injury into three discrete phases.23 24 25 Medial SMC replication begins early after injury1 and is followed at 4 days by SMC migration into the intima.3 Our previous studies showed that inhibition of the first phase, medial cell replication, with basic fibroblast growth factor antibodies had no effect on the ultimate size of the lesion.26 In the present study, we now find that inhibition of phase two, SMC migration into the intima, also does not lead to a reduction in lesion size over the long term. Therefore, even though these stages in lesion growth are important for the development of intimal lesions, it would appear that once SMCs arrive in the intima their replication rate is the ultimate determinant of lesion size. A final issue is that the lesions, under all conditions, after either continuous or delayed administration of GM 6001, achieve the same cell number and size as the control lesions. Thus, there is a suggestion of a predetermined set-point for intimal growth after arterial injury. What controls this set-point is at present unknown, but it is apparent that unless intimal cell replication can be blocked it is unlikely that lesion size will be reduced.
In summary, we have shown that a significant reduction in SMC migration resulted in a significant decrease in lesion size at early times after injury. However, prolonged SMC replication in the GM 6001–treated rats resulted in lesion size catching up to controls. These experiments suggest that although MMPs are important mediators of cell migration, inhibiting both migration and intimal cell replication will be necessary to inhibit lesion growth.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This study was supported by grant HL-03174 from the National Institutes of Health and by Bayer AG. Dr Bendeck was supported by a fellowship from the Medical Research Council of Canada. We would like to acknowledge the expert technical assistance of Lisa Stiffler and Jeff Kozlowski. We are grateful to Glycomed Inc for supplying GM 6001, the peptide MMP inhibitor used in these studies.
|
Footnotes |
|---|
Reprint requests to Michelle P. Bendeck, PhD, St Michael's Hospital Division of Cardiology, 30 Bond St, Room 811F, Toronto, Ontario, Canada M5B 1W8.
Received April 13, 1995; accepted October 3, 1995.
|
References |
|---|
|
TopAbstractIntroductionMaterials and Methods Results Discussion References |
|---|
1. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333. [Medline] [Order article via Infotrieve]
2.
Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin
D. Smooth muscle cells express urokinase during mitogenesis and
tissue-type plasminogen activator during
migration in injured rat carotid artery. Circ
Res. 1990;67:61-67.
3.
Jackson CL, Raines EW, Ross R, Reidy MA. Role
of endogenous platelet-derived growth factor in
arterial smooth muscle cell migration after balloon
catheter injury. Arterioscler Thromb. 1993;13:1218-1226.
4. Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann N Y Acad Sci. 1992;667:141-150. [Medline] [Order article via Infotrieve]
5. Jackson CL, Reidy MA. Basic fibroblast growth factor: its role in the control of smooth muscle cell migration. Am J Pathol. 1993;143:1024-1031. [Abstract]
6. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays. 1992;14:455-463. [Medline] [Order article via Infotrieve]
7.
Bendeck MP, Zempo N, Clowes A, Galardy R, Reidy
MA. Smooth muscle cell migration and matrix metalloproteinase
expression after arterial injury in the rat.
Circ Res. 1994;75:539-545.
8.
Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R,
Murphy G, Humphries S. Localization of stromelysin gene
expression in atherosclerotic plaques by in situ
hybridization. Proc Natl Acad Sci U S A. 1991;88:8154-8158.
9. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
10. Sasaguri Y, Murahashi N, Sugama K, Kato S, Hiraoka K, Satoh T, Isomoto H, Morimatsu M. Development-related changes in matrix metalloproteinase expression in human aortic smooth muscle cells. Lab Invest. 1994;71:261-269. [Medline] [Order article via Infotrieve]
11. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992;31:7152-7154. [Medline] [Order article via Infotrieve]
12. Lindner V, Olson NE, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries: interaction of heparin with basic fibroblast growth factor. J Clin Invest. 1992;90:2044-2049.
13. Jenkins GM, Crow M, Bilato C, Li Z, Ryu W, Froehlich J, Lakatta E, Cheng L. The role of MMP-2 in neointimal formation following balloon injury in the rat. FASEB J. 1994;8:A51. Abstract.
14.
Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In
vitro angiogenesis on the human arnniotic membrane: requirement for
basic fibroblast growth factor-induced proteinases.
J Cell Biol. 1989;108:671-682.
15.
Pepper MS, Belin D, Montesano R, Orci L, Vassalli
J-D. Transforming growth factor-beta 1 modulates basic
fibroblast growth factor-induced proteolytic and angiogenic
properties of endothelial cells in vitro.
J Cell Biol. 1990;111:743-755.
16.
Mignatti P, Rifkin DB. Biology and biochemistry
of proteinases in tumour invasion. Physiol Rev. 1993;73:161-195.
17.
Fisher SJ, Cui TY, Zhang L, Hartman L, Grahl K, Zhang
GY, Tarpey J, Damsky CH. Adhesive and degradative properties of
human placental cytotrophoblast cells in vitro. J
Cell Biol. 1989;109:891-902.
18. Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992;288:93-99.
19.
Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L,
Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow
MT. Migration of cultured vascular smooth muscle cells through a
basement membrane barrier requires type IV collagenase
activity and is inhibited by cellular differentiation.
Circ Res. 1994;75:41-54.
20. Adams JC, Watt FM. Regulation of development and differentiation by the extracellular matrix. Development. 1993;117:1183-1198. [Medline] [Order article via Infotrieve]
21.
Frisch SM, Francis H. Disruption of epithelial
cell-matrix interactions induces apoptosis.
J Cell Biol. 1994;124:619-626.
22. Reidy MA, Jackson J, Lindner V. Neointimal proliferation: control of vascular smooth muscle growth. Vasc Med Rev. 1992;3:156-167.
23. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation. 1992;86(suppl):43-46.
24. Reidy MA. Neointimal proliferation: the role of basic FGF on vascular smooth muscle cell proliferation. Thromb Haemost. 1993;70:172-176. [Medline] [Order article via Infotrieve]
25. Reidy MA. Growth factors and arterial smooth muscle cell proliferation. Ann N Y Acad Sci. 1994;714:225-230. [Medline] [Order article via Infotrieve]
26.
Lindner V, Reidy MA. Proliferation of smooth
muscle cells after vascular injury is inhibited by an antibody against
basic fibroblast growth factor. Proc Natl Acad Sci
U S A. 1991;88:3739-3743.
This article has been cited by other articles:
 |
|
 |
|
  R. Kundi, S. T. Hollenbeck, D. Yamanouchi, B. C. Herman, R. Edlin, E. J. Ryer, C. Wang, S. Tsai, B. Liu, and K. C. Kent Arterial gene transfer of the TGF-{beta} signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF Cardiovasc Res, November 1, 2009; 84(2): 326 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Breen, K. K. Chan, J. K. Dhaliwall, M. R. Ward, N. Al Koudsi, L. Lam, M. De Souza, H. Ghanim, P. Dandona, D. J. Stewart, et al. Insulin Increases Reendothelialization and Inhibits Cell Migration and Neointimal Growth After Arterial Injury Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1060 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Martinez-Lemus, M. A. Hill, and G. A. Meininger The Plastic Nature of the Vascular Wall: A Continuum of Remodeling Events Contributing to Control of Arteriolar Diameter and Structure Physiology, February 1, 2009; 24(1): 45 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dwivedi, S. C. Slater, and S. J. George MMP-9 and -12 cause N-cadherin shedding and thereby {beta}-catenin signalling and vascular smooth muscle cell proliferation Cardiovasc Res, January 1, 2009; 81(1): 178 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, L. Nie, M. Razavian, M. Ahmed, L. W. Dobrucki, A. Asadi, D. S. Edwards, M. Azure, A. J. Sinusas, and M. M. Sadeghi Molecular Imaging of Activated Matrix Metalloproteinases in Vascular Remodeling Circulation, November 4, 2008; 118(19): 1953 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Maile, B. E. Capps, E. C. Miller, A. W. Aday, and D. R. Clemmons Integrin-Associated Protein Association With Src Homology 2 Domain Containing Tyrosine Phosphatase Substrate 1 Regulates IGF-I Signaling In Vivo Diabetes, October 1, 2008; 57(10): 2637 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Haas, J. L. Doyle, M. R. Distasi, L. E. Norton, K. M. Sheridan, and J. L. Unthank Involvement of MMPs in the outward remodeling of collateral mesenteric arteries Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2429 - H2437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Abilleira, S. Bevan, and H. S Markus The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis J. Med. Genet., December 1, 2006; 43(12): 897 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Risinger Jr., T. S. Hunt, D. L. Updike, E. C. Bullen, and E. W. Howard Matrix Metalloproteinase-2 Expression by Vascular Smooth Muscle Cells Is Mediated by Both Stimulatory and Inhibitory Signals in Response to Growth Factors J. Biol. Chem., September 8, 2006; 281(36): 25915 - 25925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Johnson, R. Fritsche-Danielson, M. Behrendt, A. Westin-Eriksson, H. Wennbo, M. Herslof, M. Elebring, S. J. George, W. L. McPheat, and C. L. Jackson Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability Cardiovasc Res, August 1, 2006; 71(3): 586 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.G. Sluijter, D. P.V. de Kleijn, and G. Pasterkamp Vascular remodeling and protease inhibition-bench to bedside Cardiovasc Res, February 15, 2006; 69(3): 595 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Newby Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates Cardiovasc Res, February 15, 2006; 69(3): 614 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Brassard, F. Amiri, G. Thibault, and E. L. Schiffrin Role of Angiotensin Type-1 and Angiotensin Type-2 Receptors in the Expression of Vascular Integrins in Angiotensin II-Infused Rats Hypertension, January 1, 2006; 47(1): 122 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Merklinger, P. L. Jones, E. C. Martinez, and M. Rabinovitch Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension Circulation, July 19, 2005; 112(3): 423 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Johnson, Y. X. Wu, C. Herdeg, A. Baumbach, A. C. Newby, K. R. Karsch, and M. Oberhoff Stent-Based Delivery of Tissue Inhibitor of Metalloproteinase-3 Adenovirus Inhibits Neointimal Formation in Porcine Coronary Arteries Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 754 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Lalu, E. Pasini, C. J. Schulze, M. Ferrari-Vivaldi, G. Ferrari-Vivaldi, T. Bachetti, and R. Schulz Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart Eur. Heart J., January 1, 2005; 26(1): 27 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fukumoto, J.-o Deguchi, P. Libby, E. Rabkin-Aikawa, Y. Sakata, M. T. Chin, C. C. Hill, P. R. Lawler, N. Varo, F. J. Schoen, et al. Genetically Determined Resistance to Collagenase Action Augments Interstitial Collagen Accumulation in Atherosclerotic Plaques Circulation, October 5, 2004; 110(14): 1953 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Jayasankar, Y. J. Woo, L. T. Bish, T. J. Pirolli, M. F. Berry, J. Burdick, R. C. Bhalla, R. V. Sharma, T. J. Gardner, and H. L. Sweeney Inhibition of Matrix Metalloproteinase Activity by TIMP-1 Gene Transfer Effectively Treats Ischemic Cardiomyopathy Circulation, September 14, 2004; 110(11_suppl_1): II-180 - II-186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Offenberg Sweeney, P. M Cummins, Y. A Birney, J. P Cullen, E. M Redmond, and P. A Cahill Cyclic strain-mediated regulation of endothelial matrix metalloproteinase-2 expression and activity Cardiovasc Res, September 1, 2004; 63(4): 625 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Yao, Y. Chen, W. Zhai, K. Xu, W. L. Young, and G.-Y. Yang Minocycline Exerts Multiple Inhibitory Effects on Vascular Endothelial Growth Factor-Induced Smooth Muscle Cell Migration: The Role of ERK1/2, PI3K, and Matrix Metalloproteinases Circ. Res., August 20, 2004; 95(4): 364 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, G. K. Sukhova, J.-S. Sun, W.-H. Xu, P. Libby, and G.-P. Shi Lysosomal Cysteine Proteases in Atherosclerosis Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1359 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Z. Lee, B. Xu, T. Hashimoto, C. E. McCulloch, G.-Y. Yang, and W. L. Young Doxycycline Suppresses Cerebral Matrix Metalloproteinase-9 and Angiogenesis Induced by Focal Hyperstimulation of Vascular Endothelial Growth Factor in a Mouse Model Stroke, July 1, 2004; 35(7): 1715 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. W. Cheng, M. Kuzuya, T. Sasaki, K. Arakawa, S. Kanda, D. Sumi, T. Koike, K. Maeda, N. Tamaya-Mori, G.-P. Shi, et al. Increased Expression of Elastolytic Cysteine Proteases, Cathepsins S and K, in the Neointima of Balloon-Injured Rat Carotid Arteries Am. J. Pathol., January 1, 2004; 164(1): 243 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.G Sluijter, M. B Smeets, E. Velema, G. Pasterkamp, and D. P.V de Kleijn Increased collagen turnover is only partly associated with collagen fiber deposition in the arterial response to injury Cardiovasc Res, January 1, 2004; 61(1): 186 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Islam, C. D. Franco, D. W. Courtman, and M. P. Bendeck A Nonantibiotic Chemically Modified Tetracycline (CMT-3) Inhibits Intimal Thickening Am. J. Pathol., October 1, 2003; 163(4): 1557 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Akowuah, P. J. Sheridan, G. J. Cooper, and C. Newman Preventing saphenous vein graft failure: does gene therapy have a role? Ann. Thorac. Surg., September 1, 2003; 76(3): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M Aguilera, S. J George, J. L Johnson, and A. C Newby Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein Cardiovasc Res, June 1, 2003; 58(3): 679 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B Smeets, J. P.G Sluijter, M. M.P.C Donners, E. Velema, S. Heeneman, G. Pasterkamp, and D. P.V de Kleijn Increased arterial expression of a glycosylated haptoglobin isoform after balloon dilation Cardiovasc Res, June 1, 2003; 58(3): 689 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Luan, A. J. Chase, and A. C. Newby Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 769 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Morishige, H. Shimokawa, Y. Matsumoto, Y. Eto, T. Uwatoku, K. Abe, K. Sueishi, and A. Takeshita Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo Cardiovasc Res, February 1, 2003; 57(2): 572 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jones, P. J.B. Sabatini, F. S.H. Lee, M. P. Bendeck, and B. L. Langille N-Cadherin Upregulation and Function in Response of Smooth Muscle Cells to Arterial Injury Arterioscler Thromb Vasc Biol, December 1, 2002; 22(12): 1972 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsukioka, J.-i. Suzuki, M. Fujimori, Y. Wada, K. Yamaura, K.-i. Ito, R. Morishita, Y. Kaneda, M. Isobe, and J. Amano Expression of matrix metalloproteinases in cardiac allograft vasculopathy and its attenuation by anti MMP-2 ribozyme gene transfection Cardiovasc Res, December 1, 2002; 56(3): 472 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Bucciarelli, T. Wendt, W. Qu, Y. Lu, E. Lalla, L. L. Rong, M. T. Goova, B. Moser, T. Kislinger, D. C. Lee, et al. RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E-Null Mice Circulation, November 26, 2002; 106(22): 2827 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.L.M. Lamfers, J.M. Grimbergen, M.C. Aalders, M.J. Havenga, M.R. de Vries, L.G.M. Huisman, V.W.M. van Hinsbergh, and P.H.A. Quax Gene Transfer of the Urokinase-Type Plasminogen Activator Receptor-Targeted Matrix Metalloproteinase Inhibitor TIMP-1.ATF Suppresses Neointima Formation More Efficiently Than Tissue Inhibitor of Metalloproteinase-1 Circ. Res., November 15, 2002; 91(10): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cho and M. A. Reidy Matrix Metalloproteinase-9 Is Necessary for the Regulation of Smooth Muscle Cell Replication and Migration After Arterial Injury Circ. Res., November 1, 2002; 91(9): 845 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hussain, J. W. Assender, M. Bond, L.-F. Wong, D. Murphy, and A. C. Newby Activation of Protein Kinase Czeta Is Essential for Cytokine-induced Metalloproteinase-1, -3, and -9 Secretion from Rabbit Smooth Muscle Cells and Inhibits Proliferation J. Biol. Chem., July 19, 2002; 277(30): 27345 - 27352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hou, W. F. Vogel, and M. P. Bendeck Tyrosine Kinase Activity of Discoidin Domain Receptor 1 Is Necessary for Smooth Muscle Cell Migration and Matrix Metalloproteinase Expression Circ. Res., June 14, 2002; 90(11): 1147 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Li, W. J. Cantor, N. Nili, R. Robinson, L. Fenkell, Y. L. e Tran, H. A. Whittingham, W. Tsui, A. N. Cheema, J. D. Sparkes, et al. Arterial repair after stenting and the effects of gm6001, a matrix metalloproteinase inhibitor J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1852 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Bendeck Matrix Metalloproteinases: Are They Antiatherogenic but Proaneurysmal? Circ. Res., May 3, 2002; 90(8): 836 - 837. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Loftus and M. Thompson The role of matrix metalloproteinases in vascular disease Vascular Medicine, May 1, 2002; 7(2): 117 - 133. [Abstract] [PDF]
|
|
|
|
|
|
K. Kozuma, M.A. Costa, W.J. van der Giessen, M. Sabate, J.M.R. Ligthart, V.L.M.A. Coen, I.P. Kay, A.J. Wardeh, A.H.M. Knook, P.J de Feyter, et al. Initial observation regarding changes in vessel dimensions after balloon angioplasty and stenting followed by catheter-based {beta}-radiation. Is stenting necessary in the setting of catheter-based radiotherapy? Eur. Heart J., April 2, 2002; 23(8): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Bendeck, M. Conte, M. Zhang, N. Nili, B. H. Strauss, and S. M. Farwell Doxycycline Modulates Smooth Muscle Cell Growth, Migration, and Matrix Remodeling after Arterial Injury Am. J. Pathol., March 1, 2002; 160(3): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. S. Galis and J. J. Khatri Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: The Good, the Bad, and the Ugly Circ. Res., February 22, 2002; 90(3): 251 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Baker, D. R. Edwards, and G. Murphy Metalloproteinase inhibitors: biological actions and therapeutic opportunities J. Cell Sci., January 10, 2002; 115(19): 3719 - 3727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nam, A. Moralez, and D. Clemmons Vitronectin Binding to IGF Binding Protein-5 (IGFBP-5) Alters IGFBP-5 Modulation of IGF-I Actions Endocrinology, January 1, 2002; 143(1): 30 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Cherr, S. J. Motew, J. A. Travis, J. Fingerle, L. Fisher, M. Brandl, J. K. Williams, and R. L. Geary Metalloproteinase Inhibition and the Response to Angioplasty and Stenting in Atherosclerotic Primates Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E.J.M. Creemers, J. P.M. Cleutjens, J. F.M. Smits, and M. J.A.P. Daemen Matrix Metalloproteinase Inhibition After Myocardial Infarction: A New Approach to Prevent Heart Failure? Circ. Res., August 3, 2001; 89(3): 201 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Barolet, N. Nili, A. Cheema, R. Robinson, M. K. Natarajan, S. O'Blenes, J. Li, M. R. Eskandarian, J. Sparkes, M. Rabinovitch, et al. Arterial Elastase Activity After Balloon Angioplasty and Effects of Elafin, an Elastase Inhibitor Arterioscler Thromb Vasc Biol, August 1, 2001; 21(8): 1269 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Wentzel, J. Kloet, I. Andhyiswara, J. A. F. Oomen, J. C. H. Schuurbiers, B. J. G. L. de Smet, M. J. Post, D. de Kleijn, G. Pasterkamp, C. Borst, et al. Shear-Stress and Wall-Stress Regulation of Vascular Remodeling After Balloon Angioplasty : Effect of Matrix Metalloproteinase Inhibition Circulation, July 3, 2001; 104(1): 91 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Johnson, G. J. J. M. van Eys, G. D. Angelini, and S. J. George Injury Induces Dedifferentiation of Smooth Muscle Cells and Increased Matrix-Degrading Metalloproteinase Activity in Human Saphenous Vein Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1146 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Feldman, M. Mazighi, A. Scheuble, J.-F. Deux, E. De Benedetti, C. Badier-Commander, E. Brambilla, D. Henin, P. G. Steg, and M.-P. Jacob Differential Expression of Matrix Metalloproteinases After Stent Implantation and Balloon Angioplasty in the Hypercholesterolemic Rabbit Circulation, June 26, 2001; 103(25): 3117 - 3122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bellosta, M. Canavesi, E. Favari, L. Cominacini, G. Gaviraghi, R. Fumagalli, R. Paoletti, and F. Bernini Lalsoacidipine Modulates the Secretion of Matrix Metalloproteinase-9 by Human Macrophages J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 736 - 743. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Sierevogel, G. Pasterkamp, E. Velema, P. P. T. de Jaegere, B. J. G. L. de Smet, J. H. Verheijen, D. P. V. de Kleijn, and C. Borst Oral Matrix Metalloproteinase Inhibition and Arterial Remodeling After Balloon Dilation : An Intravascular Ultrasound Study in the Pig Circulation, January 16, 2001; 103(2): 302 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Leppanen, N. Janjic, M.-A. Carlsson, K. Pietras, M. Levin, C. Vargeese, L. S. Green, D. Bergqvist, A. Ostman, and C.-H. Heldin Intimal Hyperplasia Recurs After Removal of PDGF-AB and -BB Inhibition in the Rat Carotid Artery Injury Model Arterioscler Thromb Vasc Biol, November 1, 2000; 20 (11): e89 - e95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Haas, M. Milkiewicz, S. J. Davis, A. L. Zhou, S. Egginton, M. D. Brown, J. A. Madri, and O. Hudlicka Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1540 - H1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Neuville, M.-L. Bochaton-Piallat, and G. Gabbiani Retinoids and Arterial Smooth Muscle Cells Arterioscler Thromb Vasc Biol, August 1, 2000; 20(8): 1882 - 1888. [Full Text] [PDF]
|
|
|
|
|
|
B. J. G. L. de Smet, D. de Kleijn, R. Hanemaaijer, J. H. Verheijen, L. Robertus, Y. J. M. van der Helm, C. Borst, and M. J. Post Metalloproteinase Inhibition Reduces Constrictive Arterial Remodeling After Balloon Angioplasty : A Study in the Atherosclerotic Yucatan Micropig Circulation, June 27, 2000; 101(25): 2962 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Bendeck, C. Irvin, M. Reidy, L. Smith, D. Mulholland, M. Horton, and C. M. Giachelli Smooth Muscle Cell Matrix Metalloproteinase Production Is Stimulated via {alpha}v{beta}3 Integrin Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1467 - 1472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ehsan and M. J Mann Antisense and gene therapy to prevent restenosis Vascular Medicine, May 1, 2000; 5(2): 103 - 114. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ikari, K. Fujikawa, K. O. Yee, and S. M. Schwartz alpha 1-Proteinase Inhibitor, alpha 1-Antichymotrypsin, or alpha 2-Macroglobulin Is Required for Vascular Smooth Muscle Cell Spreading in Three-dimensional Fibrin Gel J. Biol. Chem., April 21, 2000; 275(17): 12799 - 12805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kanda, M. Kuzuya, M. A. Ramos, T. Koike, K. Yoshino, S. Ikeda, and A. Iguchi Matrix Metalloproteinase and {alpha}v{beta}3 Integrin-Dependent Vascular Smooth Muscle Cell Invasion Through a Type I Collagen Lattice Arterioscler Thromb Vasc Biol, April 1, 2000; 20(4): 998 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hasenstab, H. Lea, and A. W. Clowes Local Plasminogen Activator Inhibitor Type 1 Overexpression in Rat Carotid Artery Enhances Thrombosis and Endothelial Regeneration While Inhibiting Intimal Thickening Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Overhaus, J. Heckenkamp, S. Kossodo, D. Leszczynski, and G. M. LaMuraglia Photodynamic Therapy Generates a Matrix Barrier to Invasive Vascular Cell Migration Circ. Res., February 18, 2000; 86(3): 334 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hou, D. Mulholland, M. A. Gronska, and M. P. Bendeck Type VIII Collagen Stimulates Smooth Muscle Cell Migration and Matrix Metalloproteinase Synthesis after Arterial Injury Am. J. Pathol., February 1, 2000; 156(2): 467 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. George, C. T. Lloyd, G. D. Angelini, A. C. Newby, and A. H. Baker Inhibition of Late Vein Graft Neointima Formation in Human and Porcine Models by Adenovirus-Mediated Overexpression of Tissue Inhibitor of Metalloproteinase-3 Circulation, January 25, 2000; 101(3): 296 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Stringa, V Knauper, G Murphy, and J Gavrilovic Collagen degradation and platelet-derived growth factor stimulate the migration of vascular smooth muscle cells J. Cell Sci., January 6, 2000; 113(11): 2055 - 2064. [Abstract] [PDF]
|
|
|
|
|
|
H. R. Lijnen, P. Soloway, and D. Collen Tissue Inhibitor of Matrix Metalloproteinases-1 Impairs Arterial Neointima Formation After Vascular Injury in Mice Circ. Res., December 3, 1999; 85(12): 1186 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Southgate, D. Mehta, M. B. Izzat, A. C. Newby, and G. D. Angelini Increased Secretion of Basement Membrane–Degrading Metalloproteinases in Pig Saphenous Vein Into Carotid Artery Interposition Grafts Arterioscler Thromb Vasc Biol, July 1, 1999; 19(7): 1640 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Dollery, S. E. Humphries, A. McClelland, D. S. Latchman, and J. R. McEwan Expression of Tissue Inhibitor of Matrix Metalloproteinases 1 by Use of an Adenoviral Vector Inhibits Smooth Muscle Cell Migration and Reduces Neointimal Hyperplasia in the Rat Model of Vascular Balloon Injury Circulation, June 22, 1999; 99(24): 3199 - 3205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Bayer, S. L. Adamson, and B. L. Langille Atrophic Remodeling of the Artery-Cuffed Artery Arterioscler Thromb Vasc Biol, June 1, 1999; 19(6): 1499 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Giese, M. M. H. Marijianowski, O. McCook, A. Hancock, V. Ramakrishnan, L. J. Fretto, C. Chen, A. B. Kelly, J. A. Koziol, J. N. Wilcox, et al. The Role of Alpha and Beta Platelet-Derived Growth Factor Receptor in the Vascular Response to Injury in Nonhuman Primates Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 900 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Dollery, J. R. McEwan, M. Wang, Q. A. Sang, Y. E. Liu, and Y. E. Shi TIMP-4 Is Regulated by Vascular Injury in Rats Circ. Res., March 19, 1999; 84(5): 498 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. KHARE, U. KUMAR, R. SASI, L. PUEBLA, L. CALDERON, K. LEMSTROM, P. HAYRY, and A. Y. C. PATEL Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty FASEB J, February 1, 1999; 13(2): 387 - 394. [Abstract] [Full Text]
|
|
|
|
|
|
A. Kranzhofer, A. H. Baker, S. J. George, and A. C. Newby Expression of Tissue Inhibitor of Metalloproteinase-1, -2, and -3 During Neointima Formation in Organ Cultures of Human Saphenous Vein Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 255 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C Newby and A. B Zaltsman Fibrous cap formation or destruction -- the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation Cardiovasc Res, February 1, 1999; 41(2): 345 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cheng, G. Mantile, R. Pauly, C. Nater, A. Felici, R. Monticone, C. Bilato, Y. A. Gluzband, M. T. Crow, W. Stetler-Stevenson, et al. Adenovirus-Mediated Gene Transfer of the Human Tissue Inhibitor of Metalloproteinase-2 Blocks Vascular Smooth Muscle Cell Invasiveness In Vitro and Modulates Neointimal Development In Vivo Circulation, November 17, 1998; 98(20): 2195 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bellosta, D. Via, M. Canavesi, P. Pfister, R. Fumagalli, R. Paoletti, and F. Bernini HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1671 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Topol and P. W. Serruys Frontiers in Interventional Cardiology Circulation, October 27, 1998; 98(17): 1802 - 1820. [Full Text] [PDF]
|
|
|
|
|
|
M. Janiszewski, C. A Pasqualucci, L. C Souza, F. Pileggi, P. L da Luz, and F. R M. Laurindo Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway Cardiovasc Res, August 1, 1998; 39(2): 327 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Koyama and M. A. Reidy Expression of Extracellular Matrix Proteins Accompanies Lesion Growth in a Model of Intimal Reinjury Circ. Res., May 19, 1998; 82(9): 988 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Jenkins, M. T. Crow, C. Bilato, Y. Gluzband, W.-S. Ryu, Z. Li, W. Stetler-Stevenson, C. Nater, J. P. Froehlich, E. G. Lakatta, et al. Increased Expression of Membrane-Type Matrix Metalloproteinase and Preferential Localization of Matrix Metalloproteinase-2 to the Neointima of Balloon-Injured Rat Carotid Arteries Circulation, January 13, 1998; 97(1): 82 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lundgren, B. Vinogradsky, A. Guala, and S. Fujii A Vitronectin Receptor Antagonist Inhibits Neointimal Formation After Balloon Arterial Injury in Rabbits in Vivo Vascular and Endovascular Surgery, January 1, 1998; 32(1): 47 - 53. [Abstract] [PDF]
|
|
|
|
|
|
R. D. Kenagy, C. E. Hart, W. G. Stetler-Stevenson, and A. W. Clowes Primate Smooth Muscle Cell Migration From Aortic Explants Is Mediated by Endogenous Platelet-Derived Growth Factor and Basic Fibroblast Growth Factor Acting Through Matrix Metalloproteinases 2 and 9 Circulation, November 18, 1997; 96(10): 3555 - 3560. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Ellis and S. A. Whawell Vascular Smooth Muscle Cells Potentiate Plasmin Generation by Both Urokinase and Tissue Plasminogen Activator-Dependent Mechanisms: Evidence for a Specific Tissue-Type Plasminogen Activator Receptor on These Cells Blood, September 15, 1997; 90(6): 2312 - 2322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Moreno, V. H. Bernardi, J. Lopez-Cuellar, J. B. Newell, C. McMellon, H. K. Gold, I. F. Palacios, V. Fuster, and J. T. Fallon Macrophage Infiltration Predicts Restenosis After Coronary Intervention in Patients With Unstable Angina Circulation, December 15, 1996; 94(12): 3098 - 3102. [Abstract] [Full Text]
|
|
|
|
|
|
R. Forough, N. Koyama, D. Hasenstab, H. Lea, M. Clowes, S. T. Nikkari, and A. W. Clowes Overexpression of Tissue Inhibitor of Matrix Metalloproteinase-1 Inhibits Vascular Smooth Muscle Cell Functions In Vitro and In Vivo Circ. Res., October 1, 1996; 79(4): 812 - 820. [Abstract] [Full Text]
|
|
|
|
|
|
B. H. Strauss, R. Robinson, W. B. Batchelor, R. J. Chisholm, G. Ravi, M. K. Natarajan, R. A. Logan, S. R. Mehta, D. E. Levy, A. M. Ezrin, et al. In Vivo Collagen Turnover Following Experimental Balloon Angioplasty Injury and the Role of Matrix Metalloproteinases Circ. Res., September 1, 1996; 79(3): 541 - 550. [Abstract] [Full Text]
|
|
|
|
|
|
S. Li, L. H. Chow, and J. G. Pickering Cell Surface-bound Collagenase-1 and Focal Substrate Degradation Stimulate the Rear Release of Motile Vascular Smooth Muscle Cells J. Biol. Chem., November 3, 2000; 275(45): 35384 - 35392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bond, G. Murphy, M. R Bennett, A. Amour, V. Knauper, A. C. Newby, and A. H. Baker Localization of the Death Domain of Tissue Inhibitor of Metalloproteinase-3 to the N Terminus. METALLOPROTEINASE INHIBITION IS ASSOCIATED WITH PROAPOPTOTIC ACTIVITY J. Biol. Chem., December 22, 2000; 275(52): 41358 - 41363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Sierevogel, E. Velema, P. P. de Jaegere, D. P. de Kleijn, C. Borst, and G. Pasterkamp Minimal Duration of Oral Matrix Metalloproteinase Inhibition to Prevent Constrictive Arterial Remodeling after Balloon Dilation in the Pig Radiology, February 1, 2002; 222(2): 468 - 473. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||